Objectives: Co-trimoxazole (trimethoprim/sulfamethoxazole) is clinically valuable in treating skin and soft tissue infections (SSTIs) caused by community-associated methicillin-resistant Staphylococcus aureus (MRSA). The genetic basis of emerging trimethoprim/sulfamethoxazole resistance in S. aureus from Africa is unknown. Such knowledge is essential to anticipate its further spread. We investigated the molecular epidemiology of trimethoprim resistance in S. aureus collected in and imported from Africa.
Introduction
Morbidity due to Staphylococcus aureus infections is increasing around the globe 1,2 and the treatment of affected patients is complicated by the emergence of antimicrobial resistance. 3 Co-trimoxazole is a fixed-dose combination of the antifolate compounds trimethoprim and sulfamethoxazole, which act synergistically by inhibiting distinct steps in the bacterial folic acid synthesis. Currently, co-trimoxazole is valuable for the empirical antibiotic treatment of skin and soft tissue infections (SSTIs) caused by community-associated methicillin-resistant S. aureus (MRSA). 4 -7 In contrast to Europe where trimethoprim/sulfamethoxazole resistance in S. aureus is very rare, 8 up to 55% of colonizing and 72% of clinical S. aureus isolates from Africa are resistant to co-trimoxazole. 9 -13 In general, this difference is attributed to a more frequent use of antifolate compounds for the treatment and prevention of infections in sub-Saharan Africa. 9, 14 Recently, we observed that trimethoprim/sulfamethoxazole resistance is common in S. aureus causing SSTIs in travellers returning from the African continent. 15 Two genetic mechanisms of trimethoprim resistance in S. aureus are known: (i) mutation of the chromosomal dihydrofolate reductase (DHFR) gene (dfrB); and (ii) resistance genes that encode variant DHFRs, some of which are known to be located on exchangeable genetic elements. 16 -19 With regard to mutation of the autochthonous dfrB gene in S. aureus, a single functional mutation at position 98 (F98Y) confers intermediate-level trimethoprim resistance (MIC ≤256 mg/L). 16 In contrast, acquired dfr gene variants mediate high-level resistance to trimethoprim (MIC ≥512 mg/L). To date, three such genes have been identified in S. aureus of human origin: dfrA (dfrS1), dfrG and dfrK. 17 -19 In S. aureus isolated from humans, the dfrB F98Y mutation and dfrA are currently considered to be key determinants of trimethoprim resistance. 20 -23 In contrast, dfrG is perceived as being rare in S. aureus from humans, 21 but to play a role in determining trimethoprim resistance in particular clones of Staphylococcus pseudintermedius 24 and S. aureus of animal origin. 25 In 2005, Sekiguchi et al. 19 for the first time reported on dfrG in an MRSA clone in a hospital in Chiang Mai, Thailand. More recently, an outbreak of MRSA exhibiting dfrG occurred in a London hospital. 26 The third DHFR variant, dfrK, has been identified predominantly in livestock-associated MRSA from Europe and only sporadically in humans. 27, 28 Comprehensive studies on the genetic basis of trimethoprim resistance in human S. aureus from Africa are missing. Interestingly, one study from Nigeria failed to detect the supposedly common dfrA gene, 13 suggesting that other genetic determinants of trimethoprim resistance contribute to the common trimethoprim/sulfamethoxazole resistance of S. aureus from humans on the African continent. 9, 13 To this end, we conducted a multicentre cross-sectional study on trimethoprim resistance in existing S. aureus strain collections from locations in West, East, Southern and Central Africa and in staphylococci isolated at six travel clinics in Europe. Overall, we determined trimethoprim, sulfamethoxazole and trimethoprim/ sulfamethoxazole resistance and screened for dfrB mutations and additional variant dfr genes (i.e. dfrA, dfrG and dfrK) in 645 S. aureus isolates. With this study, we aim to: (i) providing a comprehensive overview on the molecular epidemiology of trimethoprim resistance in S. aureus from sub-Saharan Africa; (ii) determining the relative contribution of different trimethoprim resistance genes in S. aureus towards altered susceptibility to trimethoprim/sulfamethoxazole; and (iii) assessing the threat of emerging trimethoprim/sulfamethoxazole resistance in S. aureus through the import of resistance genes into Europe.
Methods

Strain collections
Gabon
Colonizing (n ¼ 100) and clinical isolates of S. aureus from various infections [skin and soft tissue (n ¼ 100) and bloodstream (n ¼ 12)] were collected between October 2010 and August 2012 from community dwellers in the region of Lambaré né (colonization samples) and from patients at the Albert Schweitzer Hospital, Lambaréné (clinical samples). Nasal swabs from asymptomatic subjects were taken applying the following exclusion criteria: (i) no hospitalization; or (ii) antibacterial or antituberculous treatment within 4 weeks prior to sampling. Clinical samples were obtained from patients with community-onset disease defined as a positive S. aureus culture from samples taken ≤48 h of admission. unknown site (n ¼ 4), oropharynx (n ¼ 3), eye (n ¼ 3) and bloodstream (n ¼1)] were obtained from samples processed in the microbiology laboratories of referral healthcare institutions in Ile-Ife, Ibadan and Lagos in south-west Nigeria and Maiduguri in north-east Nigeria. 13 
Nigeria II
Between December 2008 and August 2010, single nasal swabs were collected from the anterior nares of 374 adult outpatients from two HIV clinics in Lagos, Nigeria. During the same period, 370 apparently healthy adult individuals working or studying at institutions of higher education were enrolled. 9 From this collection, a total of 95 colonizing S. aureus from HIV-positive and 29 from HIV-negative individuals were randomly selected for this study.
Tanzania
In Bagamoyo district, from January 2011 to October 2012, colonizing (n ¼ 46) and clinical isolates of S. aureus from various infections [skin and soft tissue (n ¼ 39) and bloodstream (n ¼ 2)] were collected from asymptomatic community dwellers and patients at the district hospital and four healthcentres (Kiwangwa, Yombo, Mapinga and Makurunge). Samples were taken applying the same inclusion and exclusion criteria as in Gabon. 29 
Returning travellers
Since June 2011, the European Network on Imported Staphylococcus aureus (StaphTrav) systematically collects S. aureus from ill returning travellers (www.staphtrav.eu). In brief, participating travel clinics submit lesional swabs from returnees suffering from SSTIs during or 30 days after a journey outside Europe. By August 2013, the database contained a total of 250 anonymized submissions. Of these, 47 were S. aureus from independent cases with SSTIs on return from sub-Saharan Africa. Contributing centres were as follows: Tü bingen, Paul-Lechler-Krankenhaus (n ¼12); Tü bingen, Institute of Tropical Medicine (n ¼ 11); Berlin (n ¼ 9); Rotterdam (n ¼ 6); Amsterdam (n¼5); and Paris (n¼4).
Pre-travel subjects
From May 2010 to March 2011, 81 S. aureus isolates from single nasal swabs were obtained from 300 individuals consulting the University of Tü bingen travel clinic for pre-travel advice. Exclusion criteria were, within 12 months prior to sampling, hospitalization, healthcare-related occupation or travel outside Europe. This sample was chosen to represent the population of pre-travel colonizing staphylococci as a cause of SSTIs while travelling and to test the hypothesis of S. aureus acquisition abroad. Given that staphylococci causing lesions in travellers were not acquired abroad, one would expect to find similar resistance phenotypes and gene content in S. aureus from pre-travel and post-travel consultations.
Ethics statement
This research was conducted at the Institute of Tropical Medicine in Tü bingen and used S. aureus from existing strain collections together with anonymized data on type of infection or colonization. Initial sample and data collection from African and European volunteers and ill returning travellers included written informed consent and had been approved by the competent ethics committees in Africa and Europe. S. aureus causing infection in Africa were collected from routine diagnostic material, either after approval by the competent ethics committees in Gabon, Tanzania and Nigeria (Collection II) or as part of surveillance activities at hospitals in Nigeria (Collection I) and Namibia.
Antimicrobial susceptibility testing
The agar disc diffusion susceptibility testing (Kirby-Bauer) was performed as recommended by the CLSI and EUCAST using S. aureus ATCC 25923 as a control. In brief, overnight cultures were adjusted to 0.5 McFarland and cultured on EUCAST and CLSI-conforming Mueller-Hinton agar (Oxoid, Wesel, Germany). The zone of inhibition was measured after 18-24 h of incubation at 378C. All isolates were tested for resistance to trimethoprim (5 mg), sulfamethoxazole (23.75 mg), and trimethoprim/sulfamethoxazole combined (1.25 mg/23.75 mg) (BD Diagnostics, Heidelberg, Germany). The zones of inhibition for trimethoprim and trimethoprim/sulfamethoxazole were interpreted according to EUCAST clinical breakpoints. As there are no EUCAST clinical breakpoints for sulfamethoxazole as a monoagent for S. aureus, those of the CLSI were used instead.
DNA isolation
Three to four S. aureus colonies were picked from overnight cultures grown on Columbia agar with 5% sheep's blood, suspended in TE buffer pH 8.0 and incubated with 30 mg/mL lysostaphin at 378C for 30 min prior to DNA isolation with the Qiagen Blood and Tissue Kit (Qiagen GmbH, Germany) according to the manufacturer's protocol.
Genetic characterization
All isolates were characterized by multiplex PCR for the presence of mecA (forward GTAGAAATGACTGAACGTCCGATAA, reverse CCAATTCCACATTG TTTCGGTCTAA) and coa (forward CGAGACCAAGATTCAACAAG, reverse AAAGAAAACCACTCACATCA) genes. All strains were genotyped based on partial sequencing of the S. aureus protein A (spa) and assigned to spa types using the Staph Type 2.1.1 software (Ridom, Mü nster, Germany). 30 spa types were clustered into spa clonal complexes (CCs) using the Based Upon Repeat Pattern algorithm as implemented in StaphType software with parameters set to exclude spa types if repeats ,5 and to cluster these if cost ≤4. 31 dfr screening and dfrB sequencing All isolates were screened for known dfr genes in S. aureus by conventional PCR with an annealing temperature of 578C using published primers. 25 For all trimethoprim-resistant S. aureus without detectable dfrA, dfrG or dfrK genes, the DHFR-encoding dfrB was amplified using the primer set dfrB1 (5 ′ -AATTGTGTTAAATTAAAGATAACTT-3 ′ ) and dfrB2 (5 ′ -TAAGTATTCTTTAGA TAAATCGGAT-3 ′ ), sequenced and then aligned with ATCC 25923 to identify the F98Y mutation. In addition, we compared the dfrB sequences of a random sample of 172 trimethoprim-susceptible and 78 trimethoprimresistant S. aureus to explore for potential associations between other sequence variants and the resistance phenotype.
Results
Overall, 598 human S. aureus isolates from four countries in sub-Saharan Africa were analysed (Table 1) . Of these, 324 (54.2%) were resistant to trimethoprim, 127 (21.2%) to sulfamethoxazole and 114 (19.1%) to a combination of trimethoprim and sulfamethoxazole. Resistance to trimethoprim/sulfamethoxazole was only found in strains that were fully resistant to both trimethoprim and sulfamethoxazole. Accordingly, intermediate resistance to sulfamethoxazole in the presence of full trimethoprim resistance was not sufficient to render S. aureus resistant to co-trimoxazole. Similarly, all S. aureus isolates that were resistant to either trimethoprim or sulfamethoxazole whilst being susceptible or showing Figure S1 (available as Supplementary data at JAC Online)]. Among these, the dfrG gene largely predominated (94%) and, overall, occurred in half (304/598) of the S. aureus isolates from sub-Saharan Africa. In Gabon, Nigeria and Tanzania, 96% -100% of trimethoprimresistant S. aureus harboured dfrG. Notably, in trimethoprimresistant S. aureus from Namibia, dfrG prevailed (20/34), but dfrA was also common (14/34). One trimethoprim-resistant strain from Gabon (spa t1476, spa CC064) was positive for dfrG and dfrK genes concomitantly and two trimethoprim-resistant isolates (spa t1045, singleton) from Gabon were dfrA, dfrG and dfrK negative, but positive for the F98Y mutation in dfrB. None of the 274 trimethoprim-susceptible strains isolated from Africans harboured variant dfr genes. Of these, 172 (63%) were also sequenced for dfrB and none carried the F98Y mutation. Several mutations in dfrB other than F98Y could be identified in trimethoprim-resistant and -susceptible S. aureus isolates alike (data not shown).
There was no evidence of dfrG being restricted to particular S. aureus clones. S. aureus of all major spa CCs (except for spa CC939 and spa CC1510) harboured dfrG (Figure 1) . Likewise, individual spa types and the presence of dfrG did not correlate ( Figure S2 , available as Supplementary data at JAC Online).
Overall, 32 isolates of MRSA were identified ( Table 2 ). Of these, 75% were also resistant to trimethoprim/sulfamethoxazole. Similar to the findings in methicillin-susceptible S. aureus (MSSA), dfrG was present in trimethoprim-resistant MRSA from heterogeneous genetic backgrounds. The presence of dfrA in S. aureus, in contrast, clustered in MRSA spa CC064 (t064, t104 and t1443) from Namibia (n¼10) and Nigeria (n¼1), thus accounting for 11 out of 17 (65%) dfrA detected in this study.
More than half of S. aureus isolated from travellers returning from sub-Saharan Africa and suffering from SSTIs were trimethoprim resistant and also carried dfrG (Table 3 ). In contrast, none of 81 S. aureus isolates collected from nares during pre-travel consultations was trimethoprim resistant. Trimethoprim resistance caused by dfrG was more likely to be present in S. aureus from returnees compared with isolates from pre-travel consultations (x 2 test, P,0.0001). 
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Discussion
We show that dfrG is abundant and the most common genetic source of trimethoprim resistance in MSSA and MRSA from sub-Saharan Africa. We also demonstrate that dfrG can be frequently found in S. aureus from travellers returning with SSTIs from the African continent, but not in S. aureus colonizing travellers before departure. So far, dfrG has been perceived to play a minor role in human S. aureus infections 21, 27 based on its isolated occurrence in nosocomial outbreaks of MRSA in London 26 and Chiang Mai, Thailand, 19 and its otherwise sporadic description in staphylococci from animals only. 24, 25 Our findings challenge this view and refute the prevailing concept of dfrB mutations as the main source of trimethoprim resistance in human S. aureus. 16, 20, 22, 27 Moreover, our results strongly suggest importation of dfrG genes through long-distance travel.
The dfrG gene was detected in MSSA and MRSA from a wide range of genotypes and CCs (Figure 1 and Figure S2 ), suggesting that it is located on a mobile genetic element. Indeed, successful transfer of plasmid-encoded dfrG was recently demonstrated in Listeria monocytogenes. 32 Based on similar findings for dfrA and dfrK, 33 we speculate that dfrG in S. aureus may also be located on a mobile element, thus allowing its swift horizontal transfer between different S. aureus lineages. The characteristics of this element, however, remain to be determined in detail.
We show that dfrG can be found in S. aureus belonging to those spa CCs that also harbour globally important communityassociated MRSA lineages such as multilocus sequence type CC5, CC8 and CC30. Moreover, our observation on the importation of dfrG in S. aureus from ill returning travellers and previous descriptions of dfrG in MRSA causing hospital outbreaks 19, 26 underline the potential for future spread of dfrG within MRSA in populations where antifolate resistance is currently considered to be low, such as Europe and North America. 4, 7, 8 The dfrA gene accounted for 5% of trimethoprim resistance in our collection and clustered in MRSA spa CC064 from Namibia, suggesting inclusion of a locally circulating clone and thus overestimation of dfrA prevalence in S. aureus from sub-Saharan Africa in this study. Genetic sources of trimethoprim resistance other than dfrG and dfrA were rarely found among the S. aureus isolates from sub-Saharan Africa. The dfrB F98Y mutation previously described to confer intermediate-level trimethoprim resistance in S. aureus from Europe and Brazil 16 accounted for ,1% of trimethoprim resistance in sub-Saharan Africa.
For the first time, we detected dfrK in S. aureus outside of Europe: 17, 28 in one MSSA isolate (spa t1476, spa CC064, multilocus sequence type ST8) causing SSTIs in a subject from Gabon. To date, dfrK has been mainly found in livestock-associated S. aureus multilocus sequence type ST398 from Europe, 17, 28 occasionally together with dfrG, 25 as reported here. Our findings suggest that dfrK can be integrated into S. aureus of other genetic backgrounds as well and may thus be of more general importance in determining trimethoprim resistance in staphylococci. Of note, trimethoprim/sulfamethoxazole-resistant MSSA spa t1476 has previously been reported from pigs in Senegal, 34 putting our findings in line with existing evidence on the transmission of S. aureus harbouring trimethoprim resistance genes between humans and farm animals. 28 In this study, genetic screening for the additional dfr genes A, G and K or mutated dfrB fully explained the observed variation in trimethoprim susceptibility in S. aureus from sub-Saharan Africa. Moreover, we noted that sequencing did not reveal any dfrB mutation consistently associated with trimethoprim resistance other than known F98Y, a finding in line with a previous report. 19 Overall, these results suggest that genetic screening for the Zambia (n¼3) and South Africa (n¼1). c Cape Verde (n ¼1), Senegal (n¼2), Gambia (n¼2), Guinea-Bissau (n¼1), Sierra Leone (n ¼2), Ghana (n¼4), Togo (n¼1) and Nigeria (n¼2). d Kenya (n¼8), Sudan (n¼1), Rwanda (n¼1), Uganda (n ¼4), Tanzania (n¼3), Mozambique (n¼2) and Malawi (n¼2). e Cameroon (n ¼5) and Democratic Republic of Congo (n¼2). f S. aureus collected from the nares of 300 subjects during pre-travel consultations. g These nine isolates with altered susceptibility to trimethoprim belong to eight different spa types.
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presence of dfrG, dfrK, dfrA and the F98Y mutation in dfrB reliably identifies trimethoprim resistance in human S. aureus, a conclusion that, once replicated in other populations, may be of value for the development of new molecular diagnostic tools.
The abundance of dfrG in S. aureus from human infection has major implications for the development of new antifolate antibiotics. 21, 23, 35 In vitro drug testing of candidate compounds is often performed against S. aureus carrying dfrB mutations or dfrA only, 21, 23 an approach based on the prevailing view of their key role in determining trimethoprim resistance. 21 Such testing, however, may not warrant activity against S. aureus carrying other dfr genes. Indeed, one study reported that S. aureus carrying dfrG was resistant against derivatives of a new family of antifolate compounds while strains carrying dfrA or dfrB (F98Y) were killed at low concentrations. 35 Together with knowledge on substantial sequence variation between dfrG and dfrA, 17 these findings suggest that the resistance mechanism of dfrG-and dfrK-encoded DHFR differs from that of S1-DHFR (dfrA) and SaDHFR (F98Y). In light of the abundance of dfrG in S. aureus causing human infection reported here, in vitro antimicrobial testing of candidate antifolate compounds is recommended to include S. aureus expressing dfrG-or dfrK-encoded DHFR.
Our results illustrate that both trimethoprim and sulfamethoxazole resistance are necessary for the manifestation of trimethoprim/sulfamethoxazole resistance. Hence, in regions with widespread presence of dfrG in S. aureus, further emergence of co-trimoxazole resistance will be driven by changes in the prevalence of sulfamethoxazole resistance and vice versa. In this context, the fact that 11% of isolates from German control subjects showed altered sulfamethoxazole resistance (Table 3) is alarming, since the introduction of dfrG into this or similar populations may lead to a swift increase in phenotypic trimethoprim/ sulfamethoxazole resistance. Therefore, research to elucidate the prevalence and mechanisms of sulfamethoxazole resistance in S. aureus on a global scale is needed. 36 Besides, these findings illustrate that the current practice of screening for resistance against trimethoprim/sulfamethoxazole, rather than screening for resistance to trimethoprim and sulfamethoxazole separately, greatly hampers surveillance, thus allowing antimicrobial resistance to emerge silently.
We would like to emphasize that, due to the heterogeneity of populations studied and a variable degree of clonality within the samples analysed, this study is not suitable to compare the between-country prevalence of S. aureus antifolate resistance in sub-Saharan Africa. For example, half of the sample studied from Nigeria consisted of colonizing S. aureus from HIV-infected individuals, explaining the comparably higher prevalence of sulfamethoxazole resistance among trimethoprim-resistant S. aureus collected there. 9 At the same time, it has to be noted that these heterogeneities do not invalidate our findings on the dominant role of dfrG in determining common trimethoprim and trimethoprim/ sulfamethoxazole resistance in S. aureus on the African continent.
In summary, there is widespread presence of dfrG in S. aureus from sub-Saharan Africa. Together with this first report on its abundance in S. aureus from ill returning travellers, our observations allow suggesting further spread of trimethoprim resistance on a global scale and are alarming since they may foreshadow the upcoming loss of trimethoprim/sulfamethoxazole as a therapeutic option for the empirical treatment of SSTIs in the communityassociated MRSA era. 4 -7 Further research and surveillance activities are urgently needed to safeguard the future effectiveness of co-trimoxazole in treating human infections and to design new antifolate antimicrobials with activity against dfrG-encoded DHFR. Considering that dfrG can be found in staphylococci from animal origin, speculations on the exchange of resistance genes between human-and livestock-associated S. aureus seem plausible and raise serious concerns about the common use of trimethoprim in livestock husbandry.
